Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner Purchases 158,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner acquired 158,000 shares of Lyell Immunopharma stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now directly owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $0.48 on Wednesday. The company has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15. The business has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million for the quarter. Equities analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $31,000. Intech Investment Management LLC acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $52,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $52,000. Graham Capital Management L.P. acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $33,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter valued at $82,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.